Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNITE-ALS
NL-OMON60692Phase 2Recruiting
- Sponsor
- Zydus Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Usnoflast with Placebo (2 arms). Primary endpoint: Change in disease progression from baseline through 36 weeks, as measured by ALSFRS-R total score and survival. Started Jul 2026; status: recruiting.
02
Drugs
usnoflast
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON60692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60692.